Influenza virus genetics

Biomedicine and Pharmacotherapy

Volumn 54, Issue 4, 2000, Pages 196-209

  Brown, E G ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antiviral; Genetics; Influenza virus

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GENETIC ANALYSIS; HUMAN; INFLUENZA; INFLUENZA VIRUS; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS REPLICATION;

EID: 0034194673     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)89026-5     Document Type: Article

References (54)

1. Baigent SJ, Bethell RC, McCauley JW. Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro. Virology 1999 ; 263 : 323-38.
2. Bantia S, Ghate AA, Ananth SL, Babu YS, Air GM, Walsh GM. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob Agents Chemother 1998 ; 42 : 801-7.
3. Brown EG. Increased virulence of a mouse-adapted variant of influenza A/FM/1/47 is controlled by mutations in genome segments 4, 5, 7 and 8. J Virol 1990 ; 64 : 4523-33.
4. Brown EG, Bailly JE. Genetic analysis of mouse-adapted influenza A virus identifies roles for the NA, PB1, and PB2 genes in virulence. Virus Res 1999 ; 61 : 63-76.
5. Calfee DP, Hayden FG. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs 1998 ; 56 : 537-53.
6. Chen Z, Li Y, Krug RM. Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J 1999 ; 18 : 2273-83.
7. Colman PM. Neuraminidase: Enzyme and antigen. In: Krug RM, ed. The Influenza Viruses. New York: Plenum Press; 1989. p. 175-218.
8. Crosby AW. America's forgotten pandemic. The Influenza of 1918. Cambridge, MA: Cambridge University Press; 1994. p. 3-.
9. Digard P, Elton D, Bishop K, Medcalf E, Weeds A, Pope B. Modulation of nuclear localization of the influenza virus nucleoprotein through interaction with actin filaments. J Virol 1999 ; 73 : 2222-31.
10. Dunn CJ, Goa KL. Zanamivir: A review of its use in influenza. Drugs 1999 ; 58 : 761-84.
11. Elton D, Medcalf E, Bishop K, Digard P. Oligomerization of the influenza virus nucleoprotein: Identification of positive and negative sequence elements. Virology 1999 ; 260 : 190-200.
12. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999 ; 73 : 9679-82.
13. Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, et al. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 1999 ; 73 : 3184-9.
14. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998 ; 252 : 324-30.
15. Gonzalez S, Ortin J. Characterization of influenza virus PB1 protein binding to viral RNA: Two separate regions of the protein contribute to the interaction domain. J Virol 1999 ; 73 : 631-7.
16. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Infect Dis 1998 ; 178 : 1257-62.
17. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997 ; 71 : 3385-90.
18. Hatada E, Saito S, Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. J Virol 1999 ; 73 : 2425-33.
19. Hayashida H, Toh H, Kikuno R, Miyata T. Evolution of influenza genes. Mol Biol Evol 1985 ; 2 : 289-303.
20. Hayden FG. Antivirals for pandemic influenza. J Infect Dis 1997 ; 176 : S56-61.
21. Hirsch MS, Kaplan JC, D'Aquila RT. Antiviral agents. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, Vol. 1. 3rd Ed. Philadelphia: Lippincott-Raven; 1996. p. 431-66.
22. Honda A, Ishihama A. The molecular anatomy of influenza virus RNA polymerase. Biol Chem 1997 ; 378 : 483-8.
23. Hoyle L. Influenza virus genetics. In: The Influenza Viruses. Virology Monographs 4. New York: Springer-Verlag/Wein; 1968. p. 159-69.
24. Kilbourne ED. Influenza in man. In: Influenza. New York: Plenum; 1987. p. 157-218.
25. Lamb RL. Genes and proteins of influenza virus. In: Krug RM, ed. The Influenza Viruses. New York: Plenum Press; 1989. p. 1-87.
26. Lamb RL, Krug RM. Orthomyxoviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, Vol. 1. 3rd Ed. Philadelphia: Lippincott-Raven; 1996. p. 1353-95.
27. Luytjes W, Krystal M, Enami M, Pavin JD, Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989 ; 59 : 1107-13.
28. Mahy BWJ. Mutants of influenza virus. In: Palese P, Kingsbury DW, eds. The Genetics of Influenza Viruses. New York: Springer-Verlag; 1983. p. 192-254.
29. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996 ; 40 : 40-6.
30. Murphy BR, Webster RG. Orthomyxoviriuses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, Vol. 1. 3rd Ed. Philadelphia: Lippincott-Raven; 1996. p. 1397-445.
31. Nakagawa Y, Oda K, Nakada S. The PB1 subunit alone can catalyze cRNA synthesis, and the PA subunit in addition to the PB1 subunit is required for viral RNA synthesis in replication of the influenza virus genome. J Virol 1996 ; 70 : 6390-4.
32. Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3' end formation of cellular pre-mRNAs. Mol Cell 1998 ; 1 : 991-1000.
33. Neumann G, Kawaoka Y. Genetic engineering of influenza and other negative-strand RNA viruses containing segmented genomes. Adv Virus Res 1999 ; 53 : 265-300.
34. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999 ; 96 : 9345-50.
35. Neumann G, Watanabe T, Kawaoka Y. Plasmid-driven formation of influenza virus-like particles. J Virol 2000 ; 74 : 547-51.
36. O'Neill RE, Talon J, Palese P. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 1998 ; 17 : 288-96.
37. Rott R. Molecular basis of infectivity and pathogenicity of myxovirus. Arch Virol 1979 ; 59 : 285-98.
38. Rott R, Orlich M, Scholtissek C. Correlation of pathogenicity and gene constellation of influenza A viruses. III. Non-pathogenic recombinants derived from highly pathogenic parent strains. J Gen Virol 1979 ; 44 : 471-7.
39. Smeenk C, Brown EG. The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol 1994 ; 68 : 530-4.
40. Smeenk CA, Wright KE, Burns BF, Thaker AJ, Brown EG. Mutations in the hemagglutinin and matrix genes of a virulent influenza virus variant, A/FM/1/47-MA, control different stages in pathogenesis. Virus Res 1996 ; 44 : 79-95.
41. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998 ; 42 : 3234-41.
42. Tan SL, Katze MG. Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase. J Interferon Cytokine Res 1998 ; 18 : 757-66.
43. Tong N, Nakajima K, Nakajima S. Identification of the sites for suppressor mutations on the hemagglutinin molecule to temperature-sensitive phenotype of the influenza virus. Microbiol Immunol 1995 ; 39 : 687-92.
44. Tong N, Nobusawa E, Morishita M, Nakajima S, Nakajima K. M protein correlates with the receptor-binding specificity of haemagglutinin protein of reassortant influenza A (H1N1) virus. J Gen Virol 1998 ; 79 : 2425-34.
45. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993 ; 363 : 418-23.
46. Wang P, Palese P, O'Neill RE. The NPI-1/NPI-3 (karyopherin alpha) binding site on the influenza A virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol 1997 ; 71 : 1850-6.
47. Ward AC. Virulence of influenza A virus for mouse lung. Virus Genes 1997 ; 14 : 187-94.
48. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992 ; 56 : 152-79.
49. Wharton SA, Weis W, Skehel JJ, Wiley DC. Structure, function and antigenicity of the hemagglutinin of influenza virus. In: Krug RM, ed. The Influenza Viruses. New York: Plenum Press; 1989. p. 153-73.
50. Wolff T, O'Neill RE, Palese P. Interaction cloning of NS1-I, a human protein that binds to the nonstructural NS1 proteins of influenza A and B viruses. J Virol 1996 ; 70 : 5363-72.
51. Wolff T, O'Neill RE, Palese P. NS1-binding protein (NS1-BP): A novel human protein that interacts with the influenza A virus nonstructural NS1 protein is relocalized in the nuclei of infected cells. J Virol 1998 ; 72 : 7170-80.
52. Ye Z, Liu T, Offringa DP, McInnis J, Levandowski RA. Association of influenza virus matrix protein with ribonucleoproteins. J Virol 1999 ; 73 : 7467-73.
53. Yewdell JW, Taylor A, Yellen A, Caton A, Gerhard W, Bachi T. Mutations in or near the fusion peptide of the influenza virus hemagglutinin affect an antigenic site in the globular region. J Virol 1993 ; 67 : 933-42.
54. Zebedee SL, Lamb RA. Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein. Proc Natl Acad Sci USA 1989 ; 86 : 1061-5.